November 5th, 2025 Pacific Zhou Yu and Zhang Wei

Report Summary

Market Performance:

On November 4, 2025, the pharmaceutical sector fell by -1.97%, underperforming the CSI 300 index by 1.22%. It ranked 29th out of 31 sub-sectors in the industry classification of China Securities Index Co. Within the sub-sectors of pharmaceuticals, va

Industry News

Recently, UCB announced that the US FDA has approved Kygevvi for the treatment of Thymidine Kinase 2 Deficiency (TK2d) in adults and pediatric patients whose onset age is at 12 years old and below. Kygevvi is the first approved treatment for TK2d, wh

Company News

Bailitian Tianheng (688506): The company announced that its self-developed innovative biologic drug T-Bren (HER2ADC) has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration's Drug Evaluation

Dazhon Pharmaceutical (688192): The company announced that it will release the latest research results of two core products, Gaorui Zhe (Golidinitinib Capsules) and Birelentinib (DZD8586), in the field of lymphoma treatment at the 67th American Socie

Haichuang Pharmaceutical (688302): The company announced that the clinical Phase II trial of HP515, an orally administered high-selectiveTHR-β agonist developed by the company for the treatment of metabolic-associated steatohepatitis (MASH), has rece

North China Pharmaceutical (600812): The company announced that its subsidiary Huamin Pharmaceutical recently received the Approval Notice for Chemical API Market Application of Ceftobiprole issued by the National Medical Products Administration. Upo

Risk warnings: new drug research and development as well as market launch may not meet expectations; risks of intensified market competition, etc.